Ironwood Pharma (IRWD) Misses Q4 EPS by 4c, Misses on Revenue; Offers FY25 Revenue Guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q4 EPS of $0.02, $0.04 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $90.55 million versus the consensus estimate of $92.5 million.

GUIDANCE:

Ironwood Pharma sees FY2025 revenue of $260-290 million, versus the consensus of $287.6 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
• The OLB Group Reports Second Quarter 2026 Results and Completes Company-Wide Transition to AI-Assisted Software Development